Showing results (101-110 of 180) with videos related to
Sort By:
Pageof 18
Genes & Development|November 5, 2025
Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancerChunlei Shao, Alexandra Indeglia, Maya Foster, et al.Nature Communications|February 14, 2018
CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activitySergey Karakashev, Hengrui Zhu, Shuai Wu, et al.Cancer Discovery|April 18, 2026
Spatial integration of protein and chromosomal states reveals early copy number changes and genotype-associated immune neighborhoods in serous ovarian cancer evolutionTanjina Kader, Yu-An Chen, Clemens B Hug, et al.Nature Communications|September 8, 2019
ARID1A promotes genomic stability through protecting telomere cohesionBo Zhao, Jianhuang Lin, Lijie Rong, et al.Cell Reports|January 18, 2016
Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian CancerYoung Eun Choi, Khyati Meghani, Marie-Eve Brault, et al.Cell|November 7, 2002
BRCA1 supports XIST RNA concentration on the inactive X chromosomeShridar Ganesan, Daniel P Silver, Roger A Greenberg, et al.The Journal of Clinical Investigation|April 26, 2014
Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearanceRachel A Davidowitz, Laura M Selfors, Marcin P Iwanicki, et al.Proceedings of the National Academy of Sciences of the United States of America|December 24, 2014
An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinomaMaria Giuseppina Baratta, Anna C Schinzel, Yaara Zwang, et al.Nature Communications|June 3, 2020
Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogrammingYohan Suryo Rahmanto, Wenjing Shen, Xu Shi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatinGeoffrey D Girnun, Liang Chen, Jessica Silvaggi, et al.Pageof 18